0001179110-16-017816.txt : 20160119
0001179110-16-017816.hdr.sgml : 20160118
20160119160958
ACCESSION NUMBER: 0001179110-16-017816
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160114
FILED AS OF DATE: 20160119
DATE AS OF CHANGE: 20160119
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Innoviva, Inc.
CENTRAL INDEX KEY: 0001080014
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943265960
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 951 GATEWAY BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 6502389600
MAIL ADDRESS:
STREET 1: 951 GATEWAY BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: THERAVANCE INC
DATE OF NAME CHANGE: 20020207
FORMER COMPANY:
FORMER CONFORMED NAME: ADVANCED MEDICINE INC
DATE OF NAME CHANGE: 20000302
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Faerm Michael E.
CENTRAL INDEX KEY: 0001647141
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30319
FILM NUMBER: 161348433
MAIL ADDRESS:
STREET 1: C/O THERAVANCE, INC.
STREET 2: 951 GATEWAY BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
edgar.xml
FORM 4 -
X0306
4
2016-01-14
0
0001080014
Innoviva, Inc.
INVA
0001647141
Faerm Michael E.
951 GATEWAY BLVD.
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Sr VP & Chief Business Officer
Common Stock
2016-01-14
4
A
0
67126
0
A
172414
D
Includes 33,562 shares of common stock granted pursuant to a time-based restricted stock award (RSA). Twenty-five percent of the shares subject to the RSA shall vest on February 20, 2017, and 6.25% of the shares subject to the RSA shall vest quarterly thereafter on the Issuer's standard vesting dates until February 20, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date.
Includes shares of common stock granted pursuant to a performance-based restricted stock award (PSA). The shares vest pursuant to the PSA over a two-year and three-year performance period upon, and subject to a formula related to, the Issuer's achievement of certain levels of total shareholder return (TSR). The "target" number of shares that may vest is 16,782, but the actual number of shares that may vest will range from 0 to 33,564 shares based on the Issuer's TSR over the performance periods. Subject to achievement of the performance-based vesting conditions, (i) two-thirds of the shares eligible to vest based on achievement for the two-year performance period will vest on February 20, 2018 and the remaining one-third of such shares will vest on February 20, 2019 and (ii) the shares eligible to vest based on achievement for the three-year performance period will vest on February 20, 2019, in each case, (continued in Footnote 3)
(continued from Footnote 2) provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date.
/s/ Michael Faerm
2016-01-19